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Recent genome-wide association studies have identified that variants in or near
PNPLA3, NCAN, GCKR, LYPLAL1, and TM6SF2 are significantly associated with non-
alcoholic fatty liver disease (NAFLD) in multiple ethnic groups. Studies on their impact
on NAFLD in Han Chinese are still limited. In this study, we examined the relevance of
these variants to NAFLD in a community-based Han Chinese population and further
explored their potential joint effect on NAFLD. Six single nucleotide polymorphisms
(SNPs) (PNPLA3 rs738409, rs2294918, NCAN rs2228603, GCKR rs780094, LYPLAL1
rs12137855, and TM6SF2 rs58542926) previously identified in genome-wide analyses,
to be associated with NAFLD were genotyped in 384 NAFLD patients and 384 age- and
gender-matched healthy controls. We found two out of the six polymorphisms, PNPLA3
rs738409 (OR = 1.52, 95%CI: 1.19–1.96; P = 0.00087) and TM6SF2 rs58542926
(OR = 2.11, 95%CI: 1.34–3.39; P = 0.0016) are independently associated with
NAFLD after adjustment for the effects of age, gender, and BMI. Our analysis further
demonstrated the strong additive effects of the risk alleles of PNPLA3 and TM6SF2
with an overall significance between the number of risk alleles and NAFLD (OR = 1.64,
95%CI: 1.34–2.01; P = 1.4 × 10−6). The OR for NAFLD increased in an additive
manner, with an average increase in OR of 1.52 per additional risk allele. Our results
confirmed that the PNPLA3 and TM6SF2 variants were the most significant risk alleles
for NAFLD in Chinese population. Therefore, genotyping these two genetic risk factors
may help identify individuals with the highest risk of NAFLD.
Keywords: additive effects, PNPLA3, TM6SF2, NAFLD, Chinese
INTRODUCTION
Non-alcoholic fatty liver disease (NAFLD) is the most common liver disorder, whose prevalence
is estimated to be 20–30% in Western industrialized countries (Bedogni et al., 2005). Although it
is relatively less prevalent in China, the number of patients suffering NAFLD has approximately
doubled in the past two decades (Fan, 2013).
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The first genome-wide association study (GWAS) of NAFLD
performed by Romeo et al. (2008) identified that rs738409
G allele of the patatin-like phospholipase domain-containing-
3 (PNPLA3) is significantly associated with increased hepatic
fat levels and susceptibility to NAFLD. Subsequent analyses
demonstrated that PNPLA3 rs738409 is also associated with
disease severity and progression (Sookoian and Pirola, 2011).
A recent study demonstrated that the rs2294918 variant of
the PNPLA3 gene is also significantly associated with hepatic
steatosis in an Italian population, independent of rs738409
(Donati et al., 2016). Besides the variants associated with
steatosis, Chalasani et al. (2010) identified several genetic variants
associated with histologic features of NAFLD, including NAS
score, degree of fibrosis, lobular inflammation, and serum
levels of alanine aminotransferase. A subsequent study in a
cohort of European ancestry led by the GOLD Consortium
identified four additional NAFLD risk factors located in or near
neurocan gene (NCAN), glucokinase regulatory protein gene
(GCKR), lysophospholipase-like 1 gene (LYPLAL1), and protein
phosphatase 1 regulatory subunit 3b (PPP1R3B).(Speliotes et al.,
2011). Two subsequent studies aimed to verify these findings
in multiethnic cohorts. Palmer et al. (2013) tested whether
these European ancestry NAFLD-related variants were associated
with computed tomography defined hepatic steatosis in African-
and/or Hispanic-Americans. The results indicated that allele
frequency and effect size varies in different ethnic groups.
Another study led by Hernaez et al. (2013) investigated the
association between these variants and ultrasound-measured
hepatic steatosis in non-Hispanic white (NHW), non-Hispanic
black (NHB), and Mexican American (MA) participants
in National Health and Nutrition Examination Survey III
(NHANES III). The results also showed the variance of allele
frequency and effect size across ancestries (Hernaez et al., 2013).
Most recently, a new variant rs58542926 in the transmembrane
6 superfamily member 2 (TM6SF2) gene was associated with
higher liver fat through an exome-wide association study
(Kozlitina et al., 2014). A multiethnic study consisting of
957 obese children and adolescents showed that the allele
frequency and effect size of TM6SF2 rs58542926 in conferring
NAFLD risk varies in Caucasians, African Americans, and
Hispanics (Goffredo et al., 2016). Therefore, it is worthwhile
examining the association of these variants with NAFLD in
different ethnic settings. In particular, how these variants
interact with each other and contribute together to the
NAFLD susceptibility among each ethnic group remains to be
explored.
East Asian populations account to the largest proportion of
current total number of world living humans. However, they
are among the least studied populations in terms of the genetic
basis of NAFLD, which is incongruent with the fact that NAFLD
is gaining prevalence in East Asian populations. In the present
study, we aimed to evaluate the association of six previously
identified polymorphisms, PNPLA3 rs738409, rs2294918, NCAN
rs2228603, GCKR rs780094, LYPLAL1 rs12137855, and TM6SF2
rs58542926, with NAFLD in a community-based Han Chinese
population. Additionally, we analyzed the joint effects of these
genetic variants on the disease risk of NAFLD.
MATERIALS AND METHODS
Subjects
The characteristics of subjects enrolled in this study has been
described before (Wang et al., 2015). Briefly, our study included
384 ultrasound (US) diagnosed NAFLD patients and 384 age-
and gender-matched healthy controls from the same geographic
areas as the patients. All the subjects were recruited from
individuals conducting health examination in the Shanghai Jiao
Tong University Affiliated First People’s Hospital (Shanghai,
China). The mean age of both case and control groups was
45±13 years old, and both of them were consisted of 229
males and 155 females. Subjects with a history of heavy alcohol
consumption (>20 g/day) and other specific diseases that could
contribute to fatty liver, such as hepatitis B and C virus infection,
drug-induced liver disease, were excluded from the study. US-
based NAFLD diagnoses were made by one experienced operator
without knowing clinical and biochemical evaluations of the
participants. The guidelines used for diagnosis were adopted
from the Chinese National Consensus Workshop on NAFLD
(Zeng et al., 2008). Patients with moderate to severe fatty
liver diseases were selected in order to increase the diagnostic
accuracy and reliability (Hernaez et al., 2011). All subjects were
unrelated and self-reported Han Chinese living in the Shanghai
metropolitan area. The study conforms to the principles of the
Declaration of Helsinki. All the participants have given their
written informed consent, and the study method was approved
by the ethical committee of the Shanghai Jiao Tong University.
Genotyping
Genomic DNA was extracted from whole blood of each
participant according to the manufacturer’s instructions (Qiagen,
CA, USA). Genotyping was conducted using a Taqman-
based assay (Life Technologies, CA, USA) according to the
manufacturer’s instructions. Note that the TM6SF2 rs58542926
polymorphism has been genotyped in these samples in our
previous study (Wang et al., 2015). Hardy-Weinberg equilibrium
(HWE) was tested for each SNP using the program PLINK
(Version 1.07) (Purcell et al., 2007). The PPP1R3B rs4240624
was genotyped in our cohort. However, we found that the
Taqman-based genotyping of this SNP does not follow the
HWE given the deviated genotype distribution in our samples
(P = 3.592×10−49). We further sequenced the DNA fragment
containing this SNP in 20 randomly chosen samples. All
these samples demonstrated monomorphic at this variant site,
suggesting that this SNP may be a fake variant. We therefore
removed this SNP from our analysis. The information of allele
frequencies in East Asians and other populations was obtained
from The 1000 Genomes Project (Genomes Project et al., 2015).
Statistical Analysis
Chi-square test was used for the comparisons of allele
and genotype frequencies between NAFLD patients and
healthy controls. Multivariable analysis was used to assess the
independent effect of each SNP on the prevalence of NAFLD
by incorporating all six SNPs in a multiple logistic regression
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model with adjustment for age, gender, and BMI, under an
assumption of an additive genetic model for each SNP, in
which genotypes were coded as 0, 1, or 2 according to the
number of minor allele for a specific individual. Odds ratio (OR)
and 95% confidence interval (CI) were calculated in groups
with different number of risk alleles, and Chi-square test was
used for linear trend analysis. The group with 0 risk allele
was set as reference group. The proportion of narrow sense
heritability explained by susceptibility variants was estimated
based on multifactorial liability threshold model (So et al.,
2011). The median prevalence of NAFLD in China and narrow
sense heritability used for estimation is 15% (Fan, 2013) and
38.6% (Schwimmer et al., 2009), respectively. All the statistical
analyses were performed using statistical package R (version
3.2.1). P values less than 0.05 were considered statistically
significant.
RESULTS
Genetic Association between SNPs and
NAFLD
Genotyping was performed in 384 NAFLD patients and 384 age-
and gender-matched healthy controls. The genotyping call rates
for each SNP were 98.7% (PNPLA3 rs738409), 98.9% (PNPLA3
rs2294918), 97.9% (NCAN rs2228603), 99.3% (GCKR rs780094),
96.1% (LYPLAL1 rs12137855), and 95.4% (TM6SF2 rs58542926).
The genotype distribution of all SNPs were in HWE in both case
and control groups (all P > 0.05, data not shown). As shown in
Table 1, the minor allele frequency (MAF) of SNPs genotyped in
our study were comparable to the overall frequency in East Asians
reported in The 1000 Genomes Project (Genomes Project et al.,
2015).
The genotype distributions of these SNPs and their association
with NAFLD are listed in Table 2. Note that the association
between TM6SF2 rs58542926 polymorphism and NAFLD in
these samples have been reported in our previous study (Wang
et al., 2015). Two out of six variants, PNPLA3 rs738409 and
TM6SF2 rs58542926, were significantly associated with NAFLD.
The frequency of G allele of the PNPLA3 rs738409 variant was
significantly higher in NAFLD patients compared to those in
healthy controls (OR = 1.48, 95%CI: 1.20–1.82; P = 0.00023),
TABLE 1 | Minor Allele Frequency (MAF) in the present study and other
populations∗.
Variant Present study AFR AMR EAS EUR
PNPLA3 rs738409 0.38 0.12 0.48 0.35 0.23
PNPLA3 rs2294918 0.19 0.10 0.21 0.18 0.37
NCAN rs2228603 0.11 0.01 0.02 0.06 0.07
GCKR rs780094 0.45 0.13 0.36 0.48 0.41
LYPLAL1 rs12137855 0.055 0.18 0.15 0.08 0.21
TM6SF2 rs58542926 0.067 0.02 0.06 0.09 0.07
∗Allele frequencies information was collected from 1000 Genomes Project
(Genomes Project et al., 2015). AFR, African; AMR, American; EAS, East Asian;
EUR, European.
TABLE 2 | Genotype distribution and MAF of PNPLA3 rs738409, rs2294918,
NCAN rs2228603, GCKR rs780094, LYPLAL1 rs12137855, and TM6SF2
rs58542926.
Genotype NAFLD Healthy P-value∗ OR (95% CI)
PNPLA3 rs738409
CC 122 169 Ref
GC 191 174 0.0080 1.52 (1.11, 2.07)
GG 63 39 0.00055 2.24 (1.41, 3.55)
MAF (G allele) 0.42 0.33 0.00023 1.48 (1.20, 1.82)
PNPLA3 rs2294918
GG 258 240 Ref
GA 114 124 0.32 0.86 (0.63, 1.17)
AA 9 15 0.17 0.56 (0.24, 1.30)
MAF (A allele) 0.17 0.20 0.14 1.22 (0.94, 1.57)
NCAN rs2228603
CC 299 304 Ref
CT 70 70 0.92 1.02 (0.70, 1.47)
TT 9 0 – –
MAF (T allele) 0.12 0.093 0.15 0.78 ( 0.56, 1.09)
GCKR rs780094
CC 123 110 Ref
CT 189 182 0.65 0.93 (0.67, 1.29)
TT 68 91 0.051 0.67 (0.45, 1.00)
MAF (T allele) 0.43 0.48 0.062 1.21 (0.99, 1.48)
LYPLAL1 rs12137855
CC 333 325 Ref
TC 44 35 0.39 1.23 (0.77, 1.96)
TT 0 1 – –
MAF (T allele) 0.058 0.051 0.55 0.87 (0.56, 1.37)
TM6SF2 rs58542926
CC 302 333 Ref
CT 65 33 0.00054 2.17 (1.39, 3.40)
TT 0 0 – –
MAF (T allele) 0.089 0.045 0.00086 2.06 (1.34, 3.17)
∗Differences between genotype frequencies were tested using Chi-square test.
P < 0.05 was considered to be statistically significant. MAF, minor allele frequency;
NAFLD, non-alcoholic fatty liver disease; OR, odds ratio; CI, confidence interval.
and PNPLA3 GC and GG genotypes were significantly associated
with increased risk of disease (GC: OR: 1.52, 95%CI: 1.11–2.07;
P = 0.008; GG: OR: 2.24, 95%CI: 1.41–3.55; P = 0.00055).
Similarly, T allele of TM6SF2 rs58542926 was more prevalent
in the subjects with NAFLD (OR: 2.06, 95%CI: 1.34–3.17;
P = 0.00086). The rest of SNPs, PNPLA3 rs2294918, GCKR
rs780094, NCAN rs2228603, and LYPLAL1 rs12137855 did not
show any independent significant association with NAFLD in the
population.
Independent Effect of SNPs on NAFLD
In order to investigate the independent effect of each variant
on the susceptibility to NAFLD, all the six SNPs were included
in the multiple logistic regression model with age, gender, and
BMI as covariates. As shown in Table 3, PNPLA3 rs738409 and
TM6SF2 rs58542926 variants were significantly associated with
NAFLD after adjustment for age, gender and BMI (P = 0.00087
and 0.0016, respectively).
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TABLE 3 | Association between PNPLA3 rs738409, rs2294918, NCAN
rs2228603, GCKR rs780094, LYPLAL1 rs12137855, and TM6SF2
rs58542926 variants and NAFLD∗.
Variant Coefficient
estimate
Standard
error
OR (95%CI) P-value
PNPLA3 rs738409 0.42 0.13 1.52 (1.19,1.96) 0.00087
PNPLA3 rs2294918 0.024 0.15 1.02 (0.76,1.39) 0.88
NCAN rs2228603 0.13 0.19 1.14 (0.79,1.65) 0.49
GCKR rs780094 0.20 0.11 1.23 (0.99,1.53) 0.068
LYPLAL1 rs12137855 −0.038 0.25 0.96 (0.59,1.57) 0.88
TM6SF2 rs58542926 0.75 0.24 2.11 (1.34,3.39) 0.0016
∗Associations were tested using logistic regression with adjustment for age,
gender, and BMI. OR, odds ratio; CI, confidence interval.
Additive Effects of the Risk Alleles of
PNPLA3 rs738409 and TM6SF2
rs58542926 in NAFLD
We further investigated the joint effect of the risk allele of
PNPLA3 rs738409 and TM6SF2 rs58542926 on the risk of
NAFLD. Figure 1 shows the proportion of NAFLD patients
in the individuals harboring different number of risk alleles.
Ninety-six NAFLD patients did not harbor any risk alleles,
and we did not observe any individuals with four risk alleles
in our study. The proportion of NAFLD patients increased
significantly (P < 0.0001, Chi-square test for trend) along with
the increase of the number of risk alleles. The overall significance
between the number of risk alleles and NAFLD incidence is high,
with a P value of 1.4×10−6, using a logistic regression model
after adjustment for age, gender and BMI. We also plotted the
proportion of each risk allele for healthy controls and NAFLD
patients separately (Figure 2). Figure 3 shows the OR for NAFLD
in the group of patients with different number of risk alleles,
using the individuals with zero risk allele as the reference group.
As shown in the Figure 3, the risk of NAFLD increases linearly
with the number of risk alleles with an average of 1.52-fold
increase in OR for each additional risk allele. The regression line
fit excellently for the data with the R squared value of 0.992.
DISCUSSION
Using a cohort of 384 NAFLD patients and 384 age- and gender-
matched healthy controls, we confirmed that PNPLA3 rs738409
and TM6SF2 rs58542926 were independent risk factors conferred
susceptibility to NAFLD in a Han Chinese population. Moreover,
we examined the joint effects of PNPLA3 rs738409 and TM6SF2
rs58542926 polymorphisms. To our best of knowledge, this is
the first study to report the additive effect of PNPLA3 rs738409
andTM6SF2 rs58542926 polymorphisms on NAFLD in a Chinese
population.
PNPLA3 rs738409 was the first identified genetic variant
that contributes to the differences in liver fat levels and the
susceptibility to NAFLD (Romeo et al., 2008). Results in our
study confirmed the association between PNPLA3 rs738409
and increased risk for NAFLD in a Han Chinese population,
which emphasized its effects on NAFLD across multiple ethnic
FIGURE 1 | Proportion of NAFLD patient in 40, 336, 135, and 12
subjects harboring 0, 1, 2, and 3 risk alleles respectively.
groups. TM6SF2 rs58542926 was the most recently identified
genetic variant to be associated with NAFLD (Kozlitina et al.,
2014). The subsequent studies demonstrated that this variant
was also associated with the progression of NAFLD disease (Liu
et al., 2014; Dongiovanni et al., 2015). TM6SF2 rs58542926 was
initially identified in a multiethnic cohort consisting of African
Americans, European Americans, and Hispanics. In our previous
study, we first reported TM6SF2 rs58542926 polymorphism as an
independent risk factor that contributes to NAFLD in a Chinese
population (Wang et al., 2015). In the current study, we further
investigated its joint effects with PNPLA3 rs738409 on the risk
of developing NAFLD. Notably, the association between the
number of risk alleles and NAFLD incidence is very significant,
with a beta value of 1.52 and the mean OR of 4.65 in the
individuals carrying three risk alleles, suggesting the value of
early diagnosis of NAFLD by genotyping these two variants.
An additive model of risk alleles was shown to fit very well in
explaining the greater probability of NAFLD. Our findings in the
Chinese population are consistent with previous study performed
in other ethnic groups. Goffredo et al. (2016). have shown that the
hepatic fat fraction increased as the sum of risk allele in TM6SF2
rs58542926, PNPLA3 rs738409, and GCKR rs1260326 in an obese
children cohort including Caucasians, African Americans, and
Hispanics. Our study confirmed this joint effect in a Chinese
population, suggesting a new perspective in NAFLD classification
and diagnosis using risk allele number counting. Moreover, the
genetic variability in PNPLA3 rs738409, in TM6SF2 rs58542926,
and in the combined effects explained 8.2, 9.6, and 19.2% of
the heritability of NAFLD in Chinese population, respectively.
This indicates additional possible unknown risk variants yet to
be identified among Chinese NAFLD patients.
PNPLA3, which encodes a 481-residue protein, exhibits
lipase activity against triglyceride (TG) in hepatocytes and
retinyl esters in hepatic stellate cells (He et al., 2010; Huang
et al., 2011; Pirazzi et al., 2014). Missense mutation (I148M)
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FIGURE 2 | Proportion of PNPLA3 and TM6SF2 risk allele in NAFLD patients and healthy controls carrying different number of risk alleles.
FIGURE 3 | Odds ratio (ORs) (with 95% CI) for developing NAFLD is a
linear function of the number of risk alleles. ORs obtained by multiple
logistic regression after adjustment for age, gender and BMI. The actual odds
ratio numbers are as follows: 0 (reference group OR = 1), 1 [OR = 1.48
(1.06–2.08)], 2 [OR = 2.73 (1.77–4.26)], and 3 [OR = 4.65 (1.32–21.65)].
in PNPLA3 leads to a loss of function and thus promotes
hepatic steatosis by limiting triglyceride hydrolysis (He et al.,
2010; Smagris et al., 2015). Although the specific function of
TM6SF2 is still unknown, Kozlitina et al. (2014) found that the
Glu167Lys variant led to a lower levels of protein expression
than wild-type TM6SF2 in cultured hepatocytes. A subsequent
functional study indicated that the inhibition of TM6SF2 protein
expression results in reduced secretion of TG-rich lipoproteins
(TRLs), which increases cellular TG concentration (Mahdessian
et al., 2014). Therefore, these two variants seem to affect the
homeostasis processes of hepatic fat separately, whose functions
are relatively independent but synergistically involved in the
development of hepatic steatosis. Our results of the additive
effects of the risk alleles of PNPLA3 and TM6SF2 on NAFLD
were consistent with their biological functions, which highlights
the possibility to identify high risk individuals by genotyping
these two risk factors.
Inconsistent with the previous finding that GCKR rs780094
significantly increased the risk of NAFLD in obese Chinese
children (Lin et al., 2014), we did not observe significant
association between this variant and NAFLD. Given that the
sample size and alleles frequencies of our study (n = 766,
MAF = 0.45) were comparable to the previous study
(n = 797, MAF = 0.49) (Lin et al., 2014), we speculated
that GCKR rs780094 may only have a moderate effect on
NAFLD incidence in Chinese population. On the other
hand, participants enrolled in our study were adults with a
mean age of 45 years old, which introduces more possible
influence of environment in the study. The lack of consistency
for GCKR variant suggests its potential interaction with
environment. Similar to the results reported in the previous
study (Lin et al., 2014), we did not find significant associations
between either NCAN rs2228603 or LYPLAL1 rs12137855
and NAFLD in Han Chinese population. Recent studies
have shown that conditioning on the TM6SF2 variant
abolishes the association between NCAN variant and NAFLD
while the reverse does not occur (Kozlitina et al., 2014),
suggesting NCAN variant is not the causal variant associated
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with NAFLD. Our results of multivariable analysis confirmed this
finding by exploring the independent effects of individual variant
on NAFLD after conditioning on all the other SNPs. With regard
to LYPLAL1 rs12137855 variant, as shown in the Table 1, the
MAF of LYPLAL1 rs12137855 in East Asians is much lower than
those in other populations, which reduces the power to detect
the association given that our sample size is relatively small. Of
course, this could be also due to the limited effect size of this
variant in a Chinese population.
The NAFLD phenotype in our study was defined using
an US-based diagnosis, which might cause concern about
whether it is appropriate to detect NAFLD. However, according
to a meta-analysis comparing the diagnostic accuracy and
reliability of the US-based method to histology-based method
(gold standard), the US-based method was fairly good in
detecting moderate-severe fatty liver (Hernaez et al., 2011), and
multiple genetic studies using the US-based diagnosis method
have successfully demonstrated the associations between genetic
polymorphisms and NAFLD (Hernaez et al., 2013; Sookoian
et al., 2015).
CONCLUSION
We confirmed the associations between genetic variants in
PNPLA3 and TM6SF2 genes and NAFLD risk in a Han Chinese
population. We also demonstrated the additive effects of these
two genetic risk factors on conferring risk of NAFLD in Han
Chinese. The differences in allele frequencies of several other
risk alleles that were identified in other populations but are
not associated with NAFLD in Chinese indicates that additional
unknown risk alleles are yet to be identified in Han Chinese
populations.
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